Piper Sandler initiated coverage on Immatics N.V. with a new price target

10/7/24 7:57:11 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Piper Sandler initiated coverage of Immatics N.V. with a rating of Overweight and set a new price target of $19.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$IMTX

Date	Price Target	Rating	Analyst
5/28/2025	$10.00	Buy	Deutsche Bank
10/7/2024	$19.00	Overweight	Piper Sandler
11/2/2023		Overweight	Cantor Fitzgerald
3/31/2023	$12.00	Buy	Mizuho
3/24/2023	$16.00	Buy	Bryan Garnier
7/15/2021	$26.00 → $27.00	Outperform	SVB Leerink